Objectives To analyse whether the prevalence of undiagnosed HIV among (1) all women in Sweden and (2) migrant women, diagnosed with cervical intraepithelial neoplasia grade 2 or worse CIN2 + reaches the threshold of 0.1%, which has been suggested to be cost-effective for HIV testing.
(95% CI 0.04-0.08) versus 0.04% (95% CI 0.04-0.04); P = 0.017). Among migrant women, the proportion of undiagnosed HIV was higher among those with CIN2 + than among those without 
Introduction
Early HIV diagnosis is crucial for people living with HIV (PLWH) as late diagnosis (CD4 + T-cell count <350/mm 3 or AIDS) is associated with higher mortality and morbidity, increased healthcare costs, and higher risk of HIV transmission. [1] [2] [3] Deficiencies in routines for HIV testing contribute to the fact that one in seven of PLWH in the European Union and European Economic Area (EU/EEA) are estimated to be unaware of their HIV status and that approximately half of all HIV cases are diagnosed late. [4] [5] [6] The majority of women living with HIV (WLWH) in the EU/ EEA are migrants, a group at a particularly high risk of late diagnosis. 5, 7 Universal HIV testing has been estimated to be costeffective when the prevalence of undiagnosed HIV in a population reaches the threshold of 0.1%. [8] [9] [10] It is therefore recommended to test all individuals with unknown HIV status presenting with a condition/disease associated with a prevalence of undiagnosed HIV exceeding 0.1%, so-called indicator-condition-guided HIV testing. [11] [12] [13] [14] A European multi-centre study confirmed that eight indicator conditions/diseases, among them cervical dysplasia/cancer, were associated with a prevalence of undiagnosed HIV above 0.1%, although for cervical dysplasia/cancer the 95% confidence interval included 0.1%. 15 British HIV guidelines recommend HIV testing only cervical intraepithelial neoplasia grade 2 or worse (CIN2 + ), while others recommend HIV testing all degrees of cervical dysplasia/neoplasia. 12, 13 Cervical intraepithelial neoplasia (CIN) grade 1 is relatively common and is usually self-healing. 16 Although WLWH have a substantially higher risk of (CIN2 + ) than HIV-negative women do, [17] [18] [19] the prevalence of undiagnosed HIV among women diagnosed with CIN2 + in a low endemic setting, such as Sweden, is unknown. It is therefore uncertain whether universal HIV testing is indicated in this population.
The primary objective of this population-based register study was to assess the prevalence of undiagnosed HIV among women diagnosed with or without CIN2 + in Sweden and whether this reaches the threshold of 0.1%, suggested to be cost-effective for HIV testing. The secondary objective was to assess the prevalence of undiagnosed HIV among migrant women diagnosed with or without CIN2 + in Sweden.
Methods

Study population
All women born between 1940 and 1990, residing in the counties of Stockholm or Gothenburg at some point between 1990 and 2014, with at least one cervical cytology or histology registered in the Swedish National Cervical Screening Register (NKCx) were included. The counties of Stockholm and Gothenburg include the two largest cities in Sweden and these regions have been included in the NKCx since before 1990. By including women without registered cervical cytology but with a registered histology, those with a diagnosis of cervical cancer during follow up who had not attended cervical screening were still included in the analysis. Asylum-seekers
having not yet received the unique personal identification number (PIN), assigned to all individuals in Sweden at birth or on immigration, are not registered in the NKCx and therefore were not included in this study.
Data sources
Swedish National Cervical Screening Register (NKCx) The NKCx includes all cervical cytology and histology reports in Sweden (included in some regions since 1970, national inclusion since 1997), irrespective of where screening or colposcopy has taken place. The completeness of the register is high (≥90% for both cytologies and histologies). All women living in Sweden are invited to cervical cancer screening every third (aged 23-50) to fifth (aged 51-60) year and national attendance of screening is >80%. 16 WLWH are recommended annual screening. 20 National HIV register (InfCare HIV) InfCare HIV functions as a national quality register, a research database, and a clinical decision support tool including >99% of all PLWH in Sweden. 21, 22 Patients are enrolled to the register at the time of HIV diagnosis. Demographic, therapeutic, and laboratory data are collected at least every 6 months. InfCare HIV was established in 2003 and the implementation was finalised in all HIV care centers in 2008. Data on patients diagnosed before 2003 has been complemented retrospectively. We used the PIN to link InfCare HIV to our study population.
Variables and outcome definitions
Region of birth Participants were classified into six regions of birth: Sweden, Sub-Saharan Africa, Eastern Europe and Central Asia, Asia and Pacific, Latin America and Caribbean or Other (Western Europe except Sweden, USA, Canada, North Africa, and Middle East) (see Table S1 ). Women with an unknown country of birth were analysed together with women of birth region Other, as Other/unknown. In a subanalysis we defined a Migrant as born in Sub-Saharan Africa, Eastern Europe and Central Asia, Asia and Pacific, Latin America and Caribbean or Other/unknown.
Definition of CIN2 +
All women in our study with a diagnosis of CIN grade 2, grade 3, adenocarcinoma in situ (AIS) or invasive cervical cancer were identified and defined as having the outcome 
Estimation of time of HIV acquisition
To estimate the time of HIV acquisition we applied a CD4 + trajectory model. The model has been described previously. 23 In brief, the method uses an algorithm to model CD4 + T-cell decline trajectories in antiretroviral therapy (ART)-na€ ıve patients in order to estimate the time between HIV acquisition and HIV diagnosis. Factors associated with the slope of decline among identified groups of seroconverts, such as age and region of birth, are adjusted for in this model.
Definition of undiagnosed HIV at the time of CIN2
+ diagnosis After applying the CD4 trajectory model, the time of estimated HIV-seroconversion for each included woman was divided in three estimates: the earliest probable time of seroconversion, the average probable time, and the latest probable time.
A woman was defined as having an undiagnosed HIV at the time of CIN2 + diagnosis if CIN2 + was diagnosed sometime between the year of the earliest probable date of HIVseroconversion and the date of HIV diagnosis. Women diagnosed with CIN2
+ before the year of the earliest probable date of HIV-seroconversion were excluded.
Statistical analysis
Descriptive continuous data are presented as median or mean, and categorical variables are listed as numbers and percentages. The proportion of undiagnosed HIV among women with CIN2 + compared with women with a normal/mildly abnormal cytology/histology was calculated. The relative risk (RR) and corresponding 95% CI of being diagnosed with HIV among women with CIN2 + versus women without CIN2 + was calculated. Tests for significant differences in proportions were performed using Chisquare test or, when numbers were small, Fisher test. Differences in time to HIV diagnosis and level of nadir CD4 count were tested for significance using Wilcoxon rank sum test. All other continuous variables were normally distributed and differences were calculated using the t-test. Any P-value less than 0.05 was considered statistically significant. Calculations were done using STATA 13 software.
Results
The study population consisted of 960 577 women born between 1940 and 1990, living in the counties of Stockholm or Gothenburg sometime between 1990 and 2014, with at least one cervical cytology or histology registered in NKCx (Table 1) . Of these women, 62 874 had at least one registered diagnosis of CIN2 + ; of these, 175 women had CIN2 + diagnosed after HIV diagnosis and 62 653 had no HIV diagnosis ( Figure 1 ) There were 46 women who had CIN2 + diagnosed before the date of HIV diagnosis and after applying the CD4 + trajectory model, eight women were defined as having CIN2 + before estimated HIV acquisition, and 38 women were defined as having had undiagnosed HIV at the time of CIN2 + diagnosis (27 cases of CIN2 and 11 cases of CIN3) (Figure 1 ). There were 897 703 women who had at least one normal/mildly abnormal cervical cytology/histology and no diagnosis of CIN2 + ; of these women, 629 had a registered cytology/histology only after HIV diagnosis, 896 719 had no HIV diagnosis, and 355 women had at least one normal/mildly abnormal cervical cytology/histology before diagnosis of HIV (Figure 1 ).
Proportion of prevalent undiagnosed HIV
The proportion of undiagnosed HIV was higher among women with CIN2 + than among women without [0.06% (95% CI 0.04-0.08) versus 0.04% (95% CI 0.04-0.04); P = 0.017)] but did not reach the threshold of 0.1% (Table 2) . Among migrants, the proportion of undiagnosed HIV was also higher among women with CIN2 + than among women without [0.30% (95% CI 0.20-0.43) versus 0.08% (95% CI 0.07-0.10); P < 0.001] and exceeded 0.1%. For women born in Sweden there was no difference between those with and those without CIN2 + , and in neither group did the proportion exceed 0.1% [0.02% (95% CI 0.01-0.04) and 0.02% (95% CI 0.02-0.02); P = 0.29, respectively]. The highest proportion of undiagnosed HIV at the time of CIN2 + was among women born in + compared with women with no CIN2 + . For migrants, the median time from estimated HIV acquisition to HIV diagnosis was 9.8 (IQR 6.8-13.2) and 5.6 years (IQR 1.8-9.3) for those with and without CIN2 + before HIV diagnosis, respectively (P < 0.001). A majority of women had acquired HIV through heterosexual sex; 87% of women with undiagnosed HIV at the time of CIN2 + and 80% of women with no CIN2 + . Only one woman with undiagnosed HIV at the time of CIN2 + was registered as infected through intravenous drug use (IVDU), whereas among women without CIN2 + , 51 (14%) were infected through IVDU, 92% of whom were born in Sweden. Of Swedish-born women living with drug use, 67% were estimated to have acquired HIV between 1981 and 2000 (Table 3) .
Women with undiagnosed HIV at the time of CIN2 + had a significantly lower nadir CD4 + T-cell count compared with women without CIN2 + (median nadir CD4 + T-cell count 95/mm 3 versus 210/mm 3 ; P < 0.01). In particular, women born in the birth region Asia and Pacific, dominated by Thai women (80%), had a very low median nadir CD4 + T-cell count when HIV was undiagnosed at the time of CIN2 + compared with women born in the same region, without CIN2 + before HIV diagnosis (25/ mm 3 versus 180/mm 3 ; P < 0.01) ( Table 3) .
Discussion
Main findings
In this large population-based national register study we found a 0.3% prevalence of undiagnosed HIV among migrant women diagnosed with CIN2 + , which exceeds the threshold of 0.1% estimated to be cost-effective for HIV testing. [8] [9] [10] The prevalence of undiagnosed HIV among all women with CIN2 + , although significantly higher than among women without CIN2 + , did not exceed 0.1%.
Strengths and limitations
From earlier studies we know that the degree of participation in cervical screening is lower among migrant women than among Swedish-born women. 19, 24 One limitation with this study is that we could not include asylum-seeking or unregistered migrant women, as they are not registered in the NKCx due to lack of a personal identification number. This may bias our estimate of the risk of having undiagnosed HIV at the time of CIN2 + diagnosis. When defining migrants we included women with unknown country of birth but we cannot exclude that some of these women may have been born in Sweden. Yet it is highly unlikely that the number of women misclassified in this way would be so many as to bias our results.
We found a low prevalence of undiagnosed HIV among women with CIN2 + born in Sweden and no difference compared with those born in Sweden without CIN2 + . However, women born in Sweden at risk of HIV, such as people who inject drugs and sex workers, may have difficulties following the cervical screening programme, which may have led to an underestimation of the true risk among women born in Sweden.
The CD4 trajectory model was originally designed to be used mainly on a population level, but in this study we used it on an individual level to exclude women diagnosed with CIN2
+ before estimated HIV-seroconversion. As there is an uncertainty of the precision of this model on an individual level, this may have introduced a bias in our estimation of the risk of having undiagnosed HIV at the time of CIN2 + . To our knowledge this is the first register study in this context, adding to the body of knowledge regarding indicator-condition-guided HIV testing in countries with a low prevalence of HIV. We have had access to individual data from a well functioning nationwide register of cervical cytology and histology reports with high coverage and long-term follow up as well as from a virtually complete national HIV register, together providing high validity. We therefore believe that our estimates are close to the true prevalence despite being based on register data.
Interpretation
UNAIDS has set a goal that 90% of all PLWH should be diagnosed by 2020 25 and optimising HIV testing routines is crucial. The prevalence of undiagnosed HIV among all participants, although significantly higher among those diagnosed with CIN2 + , did not reach the threshold of 0.1%, but did exceed 0.05%, which has also been suggested to be cost-effective. 9 Earlier calculations of cost-effectiveness of HIV testing were made before it was clearly shown that early ART decreases HIV-associated mortality and morbidity and that PLWH who are on suppressive ART have a negligible risk of transmitting HIV. [26] [27] [28] [29] ART is now recommended to everyone at the time of HIV diagnosis irrespective of level of immunosuppression. 30 Updated calculations of costeffectiveness of HIV testing in the US suggest that more frequent testing than has previously been recommended is cost-effective for all risk groups and it is very likely that updated calculations in a European setting would find HIV screening indicated at a lower prevalence of undiagnosed HIV than 0.1%. 31 Migrant populations have been defined by the European Centre for Disease Prevention of Control (ECDC) as a priority group for HIV prevention and care and predominate among WLWH both in the EU/EEA and in Sweden. 21, 32, 33 Despite including women born in low-endemic regions in the definition of migrants, we found a prevalence of undiagnosed HIV of 0.3% among migrant women diagnosed with CIN2
+ . This indicates that HIV testing this population is cost-effective, in addition to the individual benefits of an early HIV diagnosis. The prevalence of undiagnosed HIV was high (0.08%) in migrants without CIN2 + as well, suggesting that HIV testing all migrant women with unknown status at the time of a cervical screening/gynaecological check-up may be justified. The highest prevalence of undiagnosed HIV was seen among women diagnosed with CIN2 + born in high-endemic regions (Sub-Saharan Africa 3.6%, Asia and Pacific 0.71%). Although all migrants, especially those from high-endemic regions, should be offered HIV testing on arrival to Sweden, this is not effectuated for all. In fact, half of Swedish migrants living with HIV have lived more than 1 year in Sweden at the time of HIV diagnosis and the majority of migrants in Sweden and the EU/EEA are diagnosed late. 3, 5, 7 The estimated average time between HIV infection and diagnosis is 4 years in the EU/EEA. 6 In our study, women with undiagnosed HIV at the time of CIN2 + had an estimated median time of more than 8 years between infection and diagnosis. Consequently, women with undiagnosed HIV at the time of CIN2 + were more immunosuppressed once HIV diagnosis was confirmed, particularly women from the birth region Asia and Pacific, compared with women without CIN2 + . Persistence and recurrence of CIN2 + after treatment is more common among WLWH and the most important risk factor seems to be a low CD4 + T-cell count. [34] [35] [36] ART is associated with reduction of the incidence and progression of cervical dysplasia among WLWH, further stressing the importance of identifying women with cervical dysplasia who are unaware of their HIV status.
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Conclusions
We recommend that all migrant women with unknown HIV status diagnosed with CIN2 + should be tested for HIV. Our results even indicate that HIV testing all migrant women at the time of cervical screening/gynaecologic check-up irrespective of cervical cytology results may be justified and that HIV testing all women diagnosed with CIN2 + might be considered. It is highly important to ensure that HIV is diagnosed as soon as possible to increase the possibility of effective CIN2 + treatment, to help prevent progression of cervical dysplasia, and to minimise HIV-related comorbidity, mortality, and transmission. Updated calculations of cost-effectiveness of HIV screening in a low endemic setting are needed. 
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